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Abstract
Background: Hepatitis B virus (HBV) infection is endemic in South Africa however, there is limited data on the degree of liver
disease and geographic variation in HIV/HBV coinfected individuals. In this study, we analysed data from the CIPRA-SA
‘Safeguard the household study’ in order to assess baseline HBV characteristics in HIV/HBV co-infection participants prior to
antiretroviral therapy (ART) initiation.
Methods: 812 participants from two South African townships Soweto and Masiphumelele were enrolled in a randomized
trial of ART (CIPRA-SA). Participants were tested for hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg), and
HBV DNA. FIB-4 scores were calculated at baseline.
Results: Forty-eight (5.9%) were HBsAg positive, of whom 28 (58.3%) were HBeAg positive. Of those with HBV, 29.8% had an
HBV DNA,2000 IU/ml and ALT,40 IU/ml ; 83.0% had a FIB-4 score ,1.45, consistent with absent or minimal liver disease.
HBV prevalence was 8.5% in Masiphumelele compared to 3.8% in Soweto (relative risk 2.3; 95% CI: 1.3–4.0). More
participants in Masiphumelele had HBeAg-negative disease (58% vs. 12%, p = 0.002) and HBV DNA levels #2000 IU/ml, (43%
vs. 6% p,0.007).
Conclusion: One third of HIV/HBV co-infected subjects had low HBV DNA levels and ALT while the majority had indicators of
only mild liver disease. There were substantial regional differences in HBsAg and HbeAg prevalence in HIV/HBV co-infection
between two regions in South Africa. This study highlights the absence of severe liver disease and the marked regional
differences in HIV/HBV co-infection in South Africa and will inform treatment decisions in these populations.
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Introduction
HIV and hepatitis B virus (HBV) co-infection is common in sub-
Saharan Africa with HBV infection in HIV co-infection ranging
from 5–17% in South Africa [1,2]. HIV/HBV co-infection is
associated with increased incidence of liver disease and, mortality
[3,4], when compared to HBV monoinfection. Clinical treatment
characteristics, which include HBeAg, HBV DNA, ALT, and
baseline liver fibrosis, are important predictors of HBV disease
progression and are also criteria for HBV treatment initiation.
However, these laboratory indicators and how they may vary
within populations and are not well characterised in HIV/HBV
co-infection in African populations. Neither hepatitis B prevalence
nor the distribution of its important clinical characteristics
(HBeAg, HBV DNA, or liver fibrosis) may be uniform in sub-
Saharan Africa, making application of guidelines that require these
measurements a challenge in resource limited settings in Africa.
Although HBV is considered endemic (.8%) in this region [5],
data in HBV mono-infection demonstrate wide variability’s in
HBV disease prevalence and its predictors of disease progression
in Africa [6].
The markers of particular clinical importance are HBeAg, HBV
DNA, ALT, and baseline liver fibrosis. HBeAg is a marker for
active HBV replication and elevated HBV DNA levels are
associated with cirrhosis and hepatocellular carcinoma [7,8].
Baseline liver fibrosis is indicative of disease progression. The FIB-
4 score, a non-invasive marker for liver fibrosis has shown good
sensitivity and specificity [9] for predicting mild and severe liver
disease.
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As HBV treatment paradigms in HIV co-infection evolve in
resource limited settings, it will be important to identify baseline
treatment characteristics, including the degree of liver disease, and
whether there are regional differences that may influence the
timing and initiation of ART in certain populations.
This study sought to identify baseline characteristics and their
regional variation, including those characteristics indicative of
disease progression and for the initiation of HBV therapy: HBeAg
status, HBV viremia, ALT, and liver fibrosis in HIV/HBV co-
infected patients initiating HIV therapy. We also sought to
compare baseline characteristics in those with and without HBV
co-infection. We analysed data from 812 participants from the
CIPRA-SA ‘Safeguard the household’ study, a randomised
controlled trial of ART monitoring strategies in a resource limited
setting, whose primary objective was to evaluate HIV outcomes as




The parent study was approved at the institutional review
boards of the University of Witwatersrand and the University of
Cape Town. Written informed consent was obtained from all
participants before the initiation of study procedures in the parent
study [10]. This current post-hoc analysis was performed on stored
specimens and this stored specimen and database analysis was
approved by the institutional review boards at the University of
California, Los Angeles (UCLA) and the ethics committee at the
University of the Witwatersrand, South Africa.
Study population and testing
This prospective study enrolled 812 participants over a two year
period starting in February 2005 who were randomised to the
nurse or doctor group. Participants were enrolled at two primary
health-care sites. The Soweto Township is a more urbanised
community with population estimates of 1.3 million. Masiphume-
lele in Cape Town is a peri-urban township established in 1992,
currently home to 17,000 people. Participants were $18 years of
age, had a CD4+ T-cell count ,350 cells/mm3 or a previous
AIDS defining illness, had no active opportunistic infections at the
time of enrolment and were ART naive (excluding previous single
dose NVP exposure and/or ,28 days of AZT exposure).
On enrolment CD4 count, HIV RNA, biochemistry (including
AST, ALT) and haematology studies were performed. In addition,
all participants were tested for hepatitis B surface antigen (HBsAg),
hepatitis B surface antibody (Anti-HBs), hepatitis B e antigen
(HBeAg), hepatitis B core antibody (Anti-HBc) with the Abbott
AxSYM Micro-particle Enzyme Immunoassay (MEIA) (Wiesba-
den, Germany) platform for Anti-HBs, Anti-HBc, Anti-HBe,
HBeAg, HBsAg and HBV DNA, where sample was available. The
FIB-4 score was used to assess liver fibrosis. A score of ,1.45 has a
90% predictive value of excluding advanced fibrosis [9].
HBV DNA was tested using the Abbott RealTime HBV assay
(Abbott Park, IL) a polymerase chain reaction (PCR) assay. Results
were reported in IU/ml and the lower limit of detection of this
assay was 10 IU/ml. Samples with viral loads .60 IU/ml had the
pol region sequenced. HBV drug resistance testing was performed
using a laboratory developed sequencing assay. This assay
amplified and sequenced the polymerase gene of HBV [11]. The
sequences were analysed using Sequencher version 4.8 and HBV
drug resistance and genotype determined using the HBVseq tool
on the Stanford HIV drug resistance database (http://hivdb.
stanford.edu/HBV/HBVseq/development /HBVseq.html). To
verify the genotypes obtained with the HBVseq tool, sequences
were further aligned with reference sequences of HBV genotype
A-G (GenBank reference sequences; Figure 1), using the Clustal W
alignment option within MEGA version 5.10 [12]. On completion
of alignment, neighbour-joining phylogenetic tree analysis was
performed in MEGA version 5.10 [12], using the p-distance
bootstrap model. The stability of the nodes was assessed by
bootstrap analysis (100 replicates), and bootstrap values greater
than 70% were considered confident [13].
Definitions: The term HBV infection is defined as a positive
HBsAg test. The term occult HBV infection is defined as a
negative HBsAg test but presence of HBV DNA [14,15]. These
two groups (HBV infection and occult HBV infection) were
analyzed separately as those with occult HBV infection may have
different clinical outcomes, when compared to HBV infection
(defined as a positive HBsAg test).
Statistical Analysis
We compared continuous variables using T-tests or the
Wilcoxon Rank Sum Test and discrete variables using chi-square
tests and log-binomial regression [16] . For continuous variables
we assessed normality using the Normal Probability Plot and the
Shapiro-Wilk test. We used the T-test for normally distributed
variables and the Wilcoxon Rank Sum Test for non-normally
distributed variables. All analysis was performed using SAS version
9.1.3 Service Pack 4 (SAS Institute Inc., Cary, NC, USA).
Results
The study enrolled 812 HIV infected participants, 449 (55.3%)
from the Soweto site in Johannesburg and 363 (44.7%) from the
Masiphumelele site in Cape Town. 804 (99.0%) of the study
participants were black African and 573 (70.0%) were women.
The median age in of the overall HIV-infected cohort was 32.0
years and the median CD4 count was 165.0 cells per mL (IQR
110.5 to 229.0 cells per mL) at enrolment. Of the 812 HIV-infected
participants, 48 (5.9%) were HBsAg positive. Occult HBV
infection (HBsAg negative but detectable HBV DNA) was
observed in 12 participants (1.5%).
Baseline Demographic and Serologic Characteristics in
those with HBV Infection (HBsAg positive)
The median age of those with HBV infection was 29.5 years.
Forty-four percent (21/48) were male. Excluding occult HBV
infection, 51.9% of the cohort demonstrated exposure to HBV
with at least one or more present of Anti-HBc, Anti-HBs, HBsAg,
or HBV DNA. Only 2.7% of the cohort had serology consistent
with vaccination (anti-HBs alone). Of the 48 HBsAg positive
individuals, 28/48 (58.3%) were HBeAg positive. There were no
differences in age or gender distribution in those with and without
HBeAg (Table 1). Individuals with HBeAg-positive HBV infection
had lower CD4 counts than those with HBeAg-negative HBV
infection, 147.0 and 203.0 cells/mm3, but this did not reach
statistical significance.
Baseline Virologic and Liver Disease Characteristics in
those with HBV Infection (HBsAg positive)
Seventy per cent (33/47) of HIV/HBV co-infected participants
had an HBV DNA.2000 IU/ml, only 28.0% (13/46) met criteria
for HBV treatment by one standard definition, the combination of
any elevation in ALT and HBV DNA$2000 IU/ml [17]. Of
those with HBeAg-negative disease, 45.0% (9/20) had HBV DNA
levels below 2000 IU/ml and only 11.1% (2/18) had an elevated
ALT and HBV VL$2000 IU/ml. Overall, 83.0% (39/47) HIV/
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HBV co-infected individuals had a median FIB-4 score of less than
1.45, indicative of minimal to little liver fibrosis. 94.7% (18/19)
HBeAg-negative participants had FIB-4 scores of less than 1.45.
Median ALT, AST, and FIB-4 scores were also higher in those
with HBeAg positive disease (Table 1).
Figure 1. Phylogenetic Analysis of the 37 study entry samples (six digit number, two letters) with HBV pol sequence results and
Genbank reference sequences (accession number genotype) at baseline. From this tree 32 sequences cluster with the reference genotype A
sequences, four cluster with the genotype D reference sequences and one with the genotype E reference sequences. Bootstrap values on the tree
referred to how rooted the phylogenetic tree is at the branch i.e. level of confidence. Note that samples identified as occult HBV infection are
excluded from this analysis. 37 isolates were sequenced at baseline, one isolate was sequenced after baseline and was thus not included in the tree.
doi:10.1371/journal.pone.0074900.g001
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Comparison between those with and without HBV
Infection (HBsAg postive)
HBV infection was more prevalent in men than in women with
44.0% (21/48) of participants being male in those infected with
HBV as compared to 28.5% (214/752) in those without HBV
(p,0.03). Individuals with HIV/HBV co-infection had lower CD4
counts, 150.0 vs 165.0 cells/mm3, but this did not reach statistical
significance. HIV-1 viral loads were not different between
participants with and without HBV co-infection. Median FIB-4
scores were also not different between HBV infected and
uninfected individuals, 0.78 vs. 0.77 (p = 0.34). Median ALT and
AST levels were higher in those with HBV infection; 33.0 IU/ml
vs. 21.0 IU/ml (p = 0.0001) and 42.0 vs. 28.0 IU/ml, (p = 0.0001)
respectively.
Regional Differences
There were substantial differences in HBV infection: the
prevalence in north-central South Africa in Soweto was 3.8%
compared to south western South Africa, Masiphumelele, where
the prevalence was 8.5% (relative risk 2.3; 95% CI: 1.3–4.0).
Despite a higher prevalence of HBV infection, more participants
in Masiphumelele had HBeAg-negative chronic HBV (58% vs.
12%; p = 0.002), a type associated with less severe disease.
Differences in HBeAg status were also reflected in HBV DNA
levels; the median HBV DNA in HBeAg+ and HBeAg (2) HBV
was 2.96108 and 3.56102 IU/ml, respectively (p,.0001) and
median HBV DNA levels between sites was 2.76108 and
5.86105 IU/ml in Soweto and Masiphumelele, respectively.
Twenty nine and eight tenths percent (29.8%) of all HIV/HBV
co-infected participants had HBV DNA levels #2000 IU/ml and
33% of participants had HBV DNA levels #20,000 IU/ml.
However, more HIV/HBV co-infected participants in Masiphu-
melele had HBV DNA levels #2000 IU/ml (43% vs. 6%;
p,0.007) and more participants in Soweto had both an elevated
ALT and HBV DNA$2000 IU/ML (35% vs. 24%), but this did
not reach statistical significance. There was no difference,
however, in median FIB-4 scores between HIV/HBV co-infected
participants between treatment sites (Table 2).
Table 1. Baseline Demographic and Clinical Characteristics.
HIV + HBsAg+ Occult HBV P value1 HBeAg+ HBeAg 2 P value
(n = 752) (n = 48) (n = 12) (n = 28) (n = 20)
Median Age 32.0 29.5 32.0 0.0002 30.5 29.0 0.3
Male (%) 28.5% 43.8% 33.3% 0.0264 42.9%(12/28) 45.0%(9/20) 0.8827
Median CD4 (cells/mm3),
(IQR)
165.0 150.0 112.5 0.8892 147.0 203.0 0.65
(111.0–229.0) (78.0–249.0) (80–179) (78.0–226.0) (77.0–269.0)
Median HIV viral load
(log copies/ml), (IQR)
5.1 5.2 5.2 0.5235 5.0 5.3 0.41
(4.6–5.6) (4.8–5.5) (4.9–5.6) (4.6–5.5) (4.9–5.6)
Median AST, (IQR) 28.0 42.0 32.0 0.0002 47.5 36.5 0.0084
(23.0–38.0) (29.0–60.5) (26.5–88.5) (37.0–80.5) (24.5–41.5)
Elevated AST2 22.3% 60.4% 41.7% 0.0001 71.4% 45.0% 0.0689
(168/752) (29/48) (5/12) (20/28) (9/20)
Median ALT (IQR) 21.0 33.0 32.0 0.0001 38.5 30.0 0.0251
(15.0–30.0) (22.0–55.0) (20.0–66.0) (25.0–63.5) (19.0–38.0)
Elevated ALT2 14.8% 36.2% 40.0% 0.0001 46.4% 21.1% 0.0788
(111/752) (17/47)2 (4/10)2 (13/28) (4/19)2
Median HBV DNA (IU/ml).
(IQR)
– 3.46107 2.56102 0.0001 2.96108 350.7 0.0001
(443.0–4.16108) (62.0–1.46104) (1.06108–6.06108) (107.3–2.76104)
HBV VL #2000 – 29.2% 72.7% 0.0001 3.6% 45.0% 0.0006
(14/48) (8/11)3 (1/28) (9/20)
Elevated ALT4 and HBV
VL.2000
– 28.3% 11.1% 0.0001 39.3% 11.1% 0.04
(13/46)4 (1/9)4 (11/28) (2/18)4
Median (IQR) FIB-4 Scores5 0.8 0.8 1.0 0.34 0.9 0.8 0.03
(0.6–1.1) (0.6–1.1) (0.8–1.2) (0.7–1.4) (0.6–0.8)
FIB-4 Score ,1.45 87.6% 83.0% 66.7% 0.58 75.0% 94.7% 0.20
(602/687)5 (39/47)5 (8/12)5 (21/28) (18/19)5
1Comparing HBsAg-positive to HBsAg-negative subjects.
2Elevated AST and ALT are defined as AST and ALT.40 IU/ml. ALT values are available for 47/48 HBsAg-positive, 19/20 HBeAg-positive, and 10/12 occult HBV subjects.
3HBV viral loads available for 11/12 occult HBV subjects.
4ALT and HBV viral loads available for 46/48 HBsAg-positive subjects, 18/20 HBeAg-negative, and 9/12 occult HBV subjects.
5FIB-4 score: Fibrosis 4 score, available for 687 HIV-positive but HBsAg-negative, 47/48 HBsAg-positive subjects, and 19/20 HBeAg-negative subjects.
doi:10.1371/journal.pone.0074900.t001
Liver Disease in HIV/HBV Coinfection
PLOS ONE | www.plosone.org 4 December 2013 | Volume 8 | Issue 12 | e74900
Molecular Characteristics
Of the 48 participants that were HBsAg positive, 38 were
successfully sequenced during the study, genotype A was the
predominant genotype and occurred in 87% (33/38) of cases,
followed by genotype D at 10% (4/38), genotype E was observed
in one subject. In Soweto all the genotypes identified were
genotype A apart from a single case of genotype E. In
Masiphumelele the participants were both genotype A and D.
There was no HBV drug resistance, as measured by consensus
sequencing, at baseline. Figure 1 depicts the phylogenetic
relatedness of the HBV isolates.
Comparison between HBV genotypes and baseline
characteristics
Median CD4 was lower in those with HBV genotype A,
compared to those with non-A genotypes, (147.0 vs 191.0 cells/
mm3) but this did not reach statistical significance. Conversely,
FIB-4 score was higher in those with non-genotype A (median 2.4
vs 0.8, p = 0.06) (Table 3).
Occult HBV infection
In this cohort, 12 individuals with occult HBV infection were
identified; these individuals had HBV DNA in the absence of any
serologic marker for HBV. The median CD4 was 112.5. Median
HBV viral load was 2.56102 IU/ml and median FIB-4 score was
1.0.
Discussion
In a South African HIV-1 treatment-naı̈ve cohort, HIV/HBV
co-infected participants had low levels of liver disease, as measured
by FIB-4 scores. Additionally, despite low CD4 counts
(CD4,350), only 30% of individuals had both an HBV
DNA.2000 IU/ml and elevated ALT which meet the treatment
criteria as proposed by Soriano [17]. There were also substantial
regional differences in HBV/HIV co-infection and its baseline
treatment characteristics in Southern Africa. These factors may
impact clinical decision making in HIV/HBV co-infection
individuals in sub-Saharan Africa, especially in those populations
where assessment of liver disease and HBV viral loads are
important to clinical decision-making.
Table 2. Regional Differences in Clinical Characteristics of HBV-Infected.
Soweto Masiphumelele All Participants p value
(n = 17) (n = 31) (n = 48)
Median Age 31.0 29.0 29.5 0.97
Male (%) 35.3% 48.4% 43.8% 0.3838
Median CD4 (cells/mm3) (IQR) 195.0 145.0 150.0 0.2405
(118.0–276.0) (32.0–246.0) (77.5–248.5)
Median HIV viral load (log copies/ml)
(IQR)
4.9 5.4 5.2 0.0516
(4.5–5.2) (4.8–5.6) (4.8–5.5)
HBeAg (+) 88.2% 41.9% 58.3% 0.0051
(15/17) (13/31) (28/48)
Median AST (IQR) 43.0 41.0 42.0 0.8082
(35.0–59.0) (28.0–62.0) (29.0–60.5)
Elevated AST1 58.8% 61.3% 60.4% 0.8673
(10/17) (19/31) (29/48)
Median ALT (IQR) 33.0 32.5 33.0 0.3093
(22.0–66.0) (21.0–54.0) (22.0–55.0)
Elevated ALT1 35.3% 36.7% 36.2% 0.9258
Median HBV DNA (IU/ml) (IQR) 2.76108 5.86105 3.46107 0.0067
(1.26108–4.46108) (2.76102–2.66108) (4.46102–4.16109)
HBV DNA#2000 5.9% 30.0% 21.3% 0.0169
(1/17) (9/30)2 (10/47)2
Elevated ALT1 and HBV VL.2000 35.3% 24.1% 28.3% 0.4224
(6/17) (7/29)3 (13/46)3
Median (IQR) FIB-4 Scores2 0.8 0.8 0.8 0.93
(0.6–1.1) (0.6–1.2) (0.6–1.1)
FIB-4 Score ,1.45 88.2% 79.3% 82.6% 0.64
(15/17) (23/29)4 (38/46)4
1Elevated AST and ALT are defined as AST and ALT.40 IU/ml.
2HBV viral loads available for 30/31 subjects from Masiphumelele and 47/48 total HBsAg-positive subjects.
3ALT and HBV viral loads available for 29/31 subjects from Masiphumelele and 46/48 total HBsAg-positive subjects.
4FIB-4 score: Fibrosis 4 score, available for 29/31 subjects from Masiphumelele and 46/48 total HBsAg-positive subjects.
doi:10.1371/journal.pone.0074900.t002
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Our study shows differences in baseline predictors of liver
disease when compared to Asian, European, or US cohorts, where
HBeAg prevalence and HBV DNA levels are higher in HIV/HBV
coinfected individuals [18] [19]. Other cohorts with higher
enrolment from African sites, however, have shown similar lower
prevalences of HBeAg-positive disease and low HBV DNA levels
[20–22]. Thio and colleagues demonstrated that 66% of patients
had HBV DNA,2000 IU/ml [20] and a Nigerian study
demonstrated lower HBV DNA levels than US and European
cohorts [22]. One explanation may be a difference in HBV
genotypes; in one study HBV genotypes D,E, and F were
associated with HBeAg-positive disease [20]. Another reason
may be the timing of acquisition of infection; in African sites, most
infections are thought to arise from horizontal transmission and
these infections may be associated with a higher degree of HBeAg
clearance, and subsequently, lower HBV viral loads.
The finding of regional differences in sub-Saharan Africa has
also been noted in HBV monoinfection and HIV/HBV co-
infection but this is the first large study to demonstrate such
differences in HIV/HBV co-infection within one country, where
HBV treatment guidelines are likely to be standardized. In South
Africa, regional differences in have been reported in HBV
monoinfected and HIV/HBV co-infected cohorts; low prevalences
of HBV infection have been reported in Johannesburg in HIV/
HBV co-infection [23] while HBV infection prevalence in an HIV
uninfected population in the Eastern Cape, in both urban and
rural areas, was 10.4% [24]. Others have found that HBsAg
prevalence is higher in rural areas [25,26]. Such regional
variations may be attributable to both age at acquisition and
difference in HBV genotypes. Alternatively, practices associated
with HBV transmission, such as scarification, may be more
common in rural areas.
Current WHO recommendations for the treatment of HIV/
HBV co-infection are for initiation of antiretroviral therapy for
those with chronic active HBV infection [27]. This definition is
evolving but one guideline recommends its definition as an HBV
DNA level $2000 IU/ml and an elevated ALT [17]. Our data
demonstrate that up to 30% of HIV/HBV co-infected individuals
in a South African clinical trial have low HBV DNA levels, 88%
have low levels of fibrosis, and that there is regional variation in
Table 3. HBV Genotypes and Baseline Characteristics.
HBV Genotype A Non-A HBV Genotype p value
(n = 33)1 (n = 5)1
Median Age (years) 30.0 32.0 0.3406
(27.0–32.0) (29.0–33.0)
Male (%) 42.4% 40.0% 0.9185
(14/33) (2/5)
Median CD4 (IQR) 147.0 191.0 0.7969
(75.0–236.0) (109.0–195.0)
Median HIV Viral Load (log copies/ml) (IQR) 5.2 5.9 0.3482
(4.8–5.4) (4.8–5.9)
HBeAg positive (%) 69.7% 80.0% 0.6392
(23/33) (4/5)
Median AST (IQR) 43.0 52.0 0.2966
(30.0–62.0) (44.0–108.0)
Elevated AST2 57.6% 80% 0.3565
(19/33) (4/5)
Median ALT (IQR) 32.0 65.0 0.5489
(22.0–54.0) (21.0–95.0)
Elevated ALT2 33.3% 60.0% 0.2646
(11/33) (3/5)
Median HBV DNA (IU/ml) (IQR) 2.26108 1.146106 0.2032
(6.26106–4.46108) (236.1–2.66108)
HBV VL, = 2000 18.2% 20.0% 0.2807
(6/33) (1/5)
Elevated ALT and HBV VL.2000 30.3% 40.0% 0.6654
(10/33) (2/5)
Median FIB-4 Scores3 (IQR) 0.8 2.4 0.0596
(0.6–1.1) (0.9–2.5)
FIB-4 Score3 ,1.45 87.9% 40.0% 0.024
(29/33) (2/5)
138 of 48 isolates were successfully sequenced, samples identified as occult HBV infection were excluded from this analysis.
2Elevated AST and ALT are defined as AST and ALT.40 IU/ml.
3FIB-4 score: Fibrosis 4 score.
doi:10.1371/journal.pone.0074900.t003
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HBV disease. These findings will impact populations where
regional variations exist and WHO recommendations for the
treatment of chronic active hepatitis are followed, which may
require testing for HBeAg and HBV DNA. These findings will also
impact cohorts where low HBV viral loads and presence/absence
of significant liver disease may change treatment decisions. Such
populations include pregnant women, where HBV viral loads are
predictors of perinatal HBV transmission and the long term data
on the safety of in utero exposure to TDF are still being studied,
and HIV/HBV coinfected individuals with preexisting or emerg-
ing renal disease who may not have access to other HBV therapies
such as entecavir or pegylated interferon. Future questions include
the optimal timing of initiation in HIV/HBV co-infected
individuals and a longitudinal examination of populations with
low fibrosis scores and low HBV DNA levels in African HIV/
HBV co-infected populations.
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